LifeMine Therapeutics

1.1 Identity and discovery platform

LifeMine describes itself as a clinical-stage biopharmaceutical company using digital genomic search technology from fungi to source precision medicines. BioPharma Dive reports that the company was formed in 2017; its current contact page identifies Watertown, Massachusetts, as headquarters, with additional offices in Gloucester and Basel. The company presents LIFE-001 as the first clinical proof point of this discovery approach. That establishes a coherent company identity and a tangible lead program, but not a validated repeatable discovery engine: the assigned materials do not provide an independently reviewed portfolio-conversion rate, platform productivity benchmark, or commercial revenue base. Company descriptions of the platform should therefore remain distinguished from externally demonstrated performance.[CO001, CO002, CO003, CO004]

1.2 Leadership and governance

LifeMine identifies co-founder Gregory Verdine as President and CEO. BioPharma Dive describes him as a former Harvard chemical biologist and serial biotech entrepreneur, making scientific and company-building experience visible in the public leadership narrative. The company also lists transplant surgeon Andrew Cameron on its Clinical Advisory Board, and its October 2026 news page records the board's formation. BioSpace separately reports the addition of Yves Zinggeler as chief commercial officer, but that appointment was not corroborated by another assigned source. These are useful signals of founder, clinical, and commercial coverage, not a complete governance map: the materials do not establish the full executive roster, board control, succession depth, or the division of operating authority.[CO007, CO008, CO009]

1.3 Financing and disclosure limits

LifeMine announced $263 million of financing in August 2026, comprising a $188 million Series E and a previously completed $75 million Series D. The release and independent coverage identify Milky Way Investments as the Series E lead and name new and continuing institutional and family office investors. This is gross financing, not evidence of cash still available, runway, or valuation. Published lifetime-funding totals do not reconcile: StartupRise reports $558 million, while BioPharma Dive reports roughly $580 million. The difference may reflect differing financing histories or source treatment, but the assigned evidence cannot resolve it. No valuation, share count, liquidation preference, revenue, cash balance, burn, runway, customer count, or headcount figure is established in the reviewed materials; those are diligence gaps, not zeros.[CO005, CO006, CO010, CO011, CO012, CO013, CO014]

1.4 Milestones and execution risk

The milestone record combines company announcements with independent reporting. LifeMine says LIFE-001 remains in an ongoing Phase 1 study involving more than 120 adults and projects Phase 2 kidney-transplant and Phase 1b islet-cell studies for early 2027; these are company statements and plans, not independently reviewed efficacy results. Fierce Biotech reports that the company previously laid off staff and paused its fungal platform while concentrating resources on LIFE-001, and that a GSK discovery collaboration stalled after GSK reprioritized. The 2026 financing may support a renewed push, but the sources do not quantify rehiring, current platform breadth, or the collaboration's rights and economics. As a result, the financing and clinical plan warrant attention, while execution capacity and the repeatability of the platform remain open questions.[CO004, CO015, CO016]

1.5 Exhibits

2.1 Market boundary: transplant immunosuppression, not discovery-platform spend

The evidence supports defining the near-term product market as pharmacologic prevention of organ rejection among transplant recipients: LifeMine describes LIFE-001 as a long-acting injectable for that purpose, with a Phase 2 kidney-transplant study and a Phase 1b islet-cell study planned for early 2027 (CM004, CM005). This is a clinical-development boundary, not proof of an approved product or commercial demand. Tacrolimus and other calcineurin inhibitors are status-quo comparators named in the company-issued release, while FDA material confirms established tacrolimus use in transplant care (CM006, CM008). The broad fungal discovery platform spans therapeutic areas but is not itself a measure of transplant-drug spend (CM010).[CM004, CM005, CM006, CM008, CM010]

2.2 Activity is measurable; addressable spend is not

SRTR reports more than 45,000 U.S. transplants in 2024 and says someone is added to the transplant waiting list every ten minutes (CM001, CM002). These are procedure-flow and wait-list indicators, not the number of patients eligible for LIFE-001, the number treated in a year, or the value of a drug market. A MycoStories article gives a separate global point-in-time estimate of more than 1.6 million people living with a transplanted organ, but supplies no methodology in the retained text (CM003). Those unlike units should not be added or converted into TAM. No supported source here yields annual drug spend, product price, or an eligible share, so the figure shows explicit evidence layers rather than implying a numeric funnel.[CM001, CM002, CM003, CM012]

2.3 Initial clinical segments and the still-unknown buying path

The disclosed clinical sequence is kidney transplantation first, with an islet-cell transplant study also planned; the evidence does not quantify either eligible population or establish additional indications (CM005, CM012). Transplant physicians and centers are the relevant clinical setting, but the assigned evidence does not identify LIFE-001's budget owner, procurement route, payer coverage, or willingness-to-switch threshold (CM013). FDA's tacrolimus information describes specialist prescribing and laboratory/support resources for that established drug; those are contextual workflow constraints, not proof that LIFE-001 will share the same label or requirements (CM007). The table separates disclosed trial segments from unverified commercial assumptions.[CM005, CM007, CM012, CM013]

2.4 Adoption hinges on clinical proof and financing the path to it

The main market constraint is evidence maturity: the company describes LIFE-001 as being in first-in-human development, with transplant-recipient studies planned rather than completed (CM005). The claimed differentiation from legacy calcineurin inhibitors is a company-positioned rationale, not comparative clinical evidence (CM008). FDA's description of tacrolimus use also illustrates that transplant immunosuppression is managed by experienced clinicians and resourced facilities (CM007). Separately, Fierce Biotech reported company statements about reallocating staff and capital toward LIFE-001 and multiple indications, while the number of affected employees was not disclosed (CM009). That is a company-specific development constraint, not evidence of market demand or a market-wide slowdown. Pricing, reimbursement, and adoption data remain diligence requirements (CM012, CM013).[CM005, CM007, CM008, CM009, CM012, CM013]

3.1 Incumbents and substitution

LifeMine’s 2026 materials place LIFE-001 in a transplant-immunosuppression contest with tacrolimus, cyclosporine, and voclosporin, while independent reporting describes its intended move into kidney and islet-cell transplantation (CP001, CP003, CP004). The strongest established comparator in the retained evidence is tacrolimus: a drug monograph lists it for rejection prophylaxis in kidney transplant patients and describes comparative outcome advantages over cyclosporine alongside metabolic and neurological trade-offs (CP006, CP007). This is an incumbent with an established treatment role, not a measured market-share benchmark. ClinicalTrials.gov lists 27,759 U.S. kidney transplants in 2024, up 1.6% from 2023, which grounds the relevant transplant population but does not quantify the addressable drug market or the share open to substitution (CP008). The competitor table therefore distinguishes evidenced alternatives from thinly documented adjacent agents rather than implying a complete immunosuppression landscape.[CP001, CP003, CP004, CP006, CP007, CP008]

3.2 Differentiation versus clinical proof

LifeMine describes LIFE-001 as a direct calcineurin inhibitor that avoids the immunophilin-dependent “molecular glue” mechanism it attributes to legacy calcineurin inhibitors; BioPharma Dive independently reported the same company-described distinction (CP003). The product is also being tested as a subcutaneous single- and multiple-ascending-dose therapy, while the registry identifies a Phase I study in healthy volunteers and says no results are posted (CP004, CP005). BioPharma Dive reported the company’s plan for later kidney-transplant and islet-cell studies, but those plans are not clinical proof of efficacy, safer use, or improved adherence (CP004). Against tacrolimus, the available comparison is thus mechanism and development stage versus established use and a documented adverse-effect profile—not a head-to-head performance result. The matrix and ordinal map make this asymmetry visible; the map’s positions are analyst-scored from the cited evidence and are not measured clinical outcomes.[CP003, CP004, CP005, CP006, CP007]

3.3 Durability, access, and unresolved economics

The strategic moat is not yet proven by clinical differentiation alone. Fierce Biotech reported LifeMine’s claim to a 65,000-sample deep-sequenced fungal library and described pharma exits from fungal discovery as CEO Greg Verdine’s characterization, not as an independent market benchmark (CP011, CP014). The historical GSK alliance provides a route to partnered discovery, with GSK taking development responsibility after investigational-new-drug filing under the 2022 terms reported by MedCity News (CP009, CP010); separate reporting says LifeMine has considered eventual self-commercialization (CP012). These routes could broaden access to capital or expertise, but the retained sources do not establish center-level switching costs, incumbent response, product pricing, or payer willingness to reimburse a new regimen. Those are decisive durability questions because a novel mechanism must displace entrenched protocols on outcomes, safety, administration burden, and economics. The pricing table records the evidence gap rather than treating missing disclosure as a zero price or a cost advantage.[CP009, CP010, CP011, CP012, CP013, CP014]

3.4 Exhibits

4.1 Financing announcements do not establish available cash

LifeMine's August 2026 news index lists a company announcement titled “LifeMine Raises $263 Million,” while a CEO-attributed article describes the $263 million as a $188 million Series E plus a previously completed $75 million Series D (CI001, CI002, CI003). These are financing-event amounts, not a reported current cash balance. The recorded lifetime totals differ: FundedIQ lists $413 million across three rounds, the CEO-attributed account says approximately $558 million, and Forge displays $522.71 million total funding alongside a $150.54 million Series E entry and $469.78 million post-money valuation (CI004, CI005, CI006). Forge says its post-money valuation is estimated from company-submitted incorporation certificates and disclaims independent verification (CI007). These records have different methods and scopes; none is an audited financing reconciliation or a liquidity measure.[CI001, CI002, CI003, CI004, CI005, CI006, CI007]

4.2 The disclosed capital plan is clinical, not commercial

The company-attributed account says financing proceeds will support clinical development of LIFE-001 and advance its transplantation and immunology pipeline; it describes plans for a Phase 2 kidney-transplant study and a Phase 1b islet-cell-transplant study (CI008, CI009). This establishes a stated use and development plan, not the amount allocated to either study, a timing-adjusted budget, or a path to recognized revenue. The assigned evidence contains no supported product price, realized revenue, royalty, milestone-payment, or revenue-recognition figure for underwriting (CI015). LifeMine's economic model therefore remains dependent on financing and/or future partnering or product commercialization, with the economics of any such arrangement unproven in this evidence set.[CI008, CI009, CI015]

4.3 Private operating metrics block underwriting

The retained evidence does not provide a current company revenue or ARR, list or realized pricing, gross margin, cost of goods, customer-acquisition cost, or payback period (CI015). It likewise does not report current cash, operating burn, runway, debt obligations, or a fully costed milestone bridge (CI016). These are unknowns, not zeros. A Fierce Biotech report describes staff reductions and consolidation of operations, but says the company had not provided the number of employees affected or whether LIFE-001 was its only pipeline asset at publication (CI010, CI011). Restructuring is a material capital-allocation signal, not a quantified savings estimate. A decision-grade model requires company financial statements, trial and external-R&D budgets, and a cash forecast through the next clinical value inflection.[CI010, CI011, CI015, CI016]

4.4 Capital-market context does not resolve company-level risk

J.P. Morgan's July 2026 report records $16.3 billion of biopharma venture funding across 235 rounds in H1 2026 and says later-stage rounds received 71% of deployed capital, versus 62% in 2025 (CI012, CI013). EY's 2026 industry report, also summarized by BioProcess International, describes a market where financing and revenue are concentrated; its aggregate industry figures are not a LifeMine revenue or margin benchmark (CI014). These data show an active but selective financing market, not assured access to future capital. The financial verdict is therefore conditional: disclosed fundraising supports continued clinical work, while unresolved liquidity, trial-cost, financing-reconciliation, and commercial-economics questions prevent a reliable runway, dilution, or unit-economics assessment.[CI012, CI013, CI014, CI016]

5.1 A fungal-genomics engine whose output still needs experimental proof

LifeMine’s product is a discovery-and-development system rather than a standalone software product: public descriptions connect fungal genomic search and a deep-sequenced strain collection to bioinformatics, machine learning, synthetic biology, microbiology, and medicinal chemistry. MTEC describes LifeBank at 100,000 wild-type fungi across more than 25,000 species, while Fierce independently reports sequencing across 100,000 strains and organization into biosynthetic-pathway clusters. Those counts describe source material and platform inputs, not the number of validated molecules or medicines. Fierce also relays 1,200 potential targets and a planned use of AI agents; the article does not establish that the target set or planned AI workflow has generated reproducible leads. The platform’s differentiation is therefore a potentially broad biological search space and integrated wet-lab capability, with hit quality, target validation, and conversion rates remaining unquantified in this evidence set. The map below keeps reported inputs, planned computation, experimental translation, and clinical output distinct.[CE001, CE002, CE003, CE004, CE005]

5.2 The critical path runs from predicted clusters to validated chemistry

The disclosed architecture is plausible but the public descriptions compress several technically distinct steps. Genome sequencing and cluster identification must be followed by prioritization, compound production or synthesis, structural confirmation, target engagement, and biological validation before a candidate becomes a drug program. The technical article on fungal biosynthetic gene clusters identifies a concrete cross-species expression problem: eukaryotic clusters may require refactoring of coding regions for heterologous expression in yeast. That is relevant field context, not evidence that LifeMine uses yeast or has failed at this step. Similarly, a 2026 review describes AI methods across genome mining, metabolomic annotation, cluster-to-metabolite linking, and pathway activation, but does not validate LifeMine’s algorithms. Public sources do not disclose a platform benchmark, conversion funnel, compound-recovery rate, target-validation rate, or comparative performance against conventional discovery. These gaps make the internal handoff from digital prediction to experimental confirmation the core diligence item, rather than the raw size of the fungal collection.[CE001, CE003, CE004, CE006, CE014]

5.3 LIFE-001 is the clearest product, but reported clinical timing is not outcome evidence

LIFE-001 is the lead product with the clearest public definition: LifeMine describes a long-acting injectable calcineurin activation inhibitor designed to avoid immunophilin-dependent organ damage associated with legacy inhibitors. BioPharma Dive describes direct binding to a previously unseen site on calcineurin; that mechanism is a reported characterization, not independent proof of clinical benefit. LifeMine’s news page records first participant dosing in a first-in-human Phase 1 study on April 8, 2025. Later coverage reported planned Phase 1b islet-transplant and Phase 2 kidney-transplant studies, but publication timing differs: Fierce described early-2027 starts while BioPharma Dive gave expected data windows of end-2027 for islet transplantation and 2028 for kidney transplantation. Those are forecasts from separate reports, not completed milestones. The cited CEO safety statement about more than 100 healthy volunteers is attributed company commentary; the reviewed articles do not supply a complete protocol or full clinical dataset. Diligence should distinguish trial initiation, planned cohorts, reported biological rationale, and evidence of efficacy or comparative safety.[CE007, CE008, CE009, CE010, CE011, CE012, CE013]

5.4 Underwriting should focus on reproducibility, clinical evidence, and control systems

The evidence supports a differentiated discovery thesis and a clinical lead, but not yet an independently testable account of platform productivity. The 100,000-strain collection, target count, and early AI-agent plan are useful descriptions of inputs and roadmap; none is a substitute for disclosed benchmark datasets, reproducible compound-generation methods, or validated target-to-candidate yield. For LIFE-001, the critical next evidence is protocol-level design, complete safety and pharmacokinetic/pharmacodynamic results, and interpretable efficacy data from transplant studies, with the report’s different timeline estimates reconciled against actual trial records. The assigned sources also do not establish manufacturing scale-up, formulation stability, release specifications, integration interfaces, cybersecurity, privacy handling, or a detailed quality-management system. Those items remain evidence gaps rather than evidence of a deficiency. The product thesis is credible enough to track, but the source set leaves platform reproducibility and clinical risk questions open.[CE004, CE005, CE006, CE012, CE013, CE014]

5.5 Exhibits

6.1 Buyer, user, and beneficiary are different groups

A third-party company profile characterizes LifeMine as B2B with product sales as its revenue model, but that classification is not evidence of realized product revenue. A potential economic buyer is a pharmaceutical partner licensing or co-developing assets; transplant centers and clinical investigators would be operational users during trials, while transplant recipients are intended beneficiaries rather than buyers. LifeMine's own listing describes medicines intended for patients, and public provider pages show that transplant care involves multidisciplinary teams and referral pathways. None of those provider pages establishes a relationship with LifeMine. The distinction matters: partner participation, patient need, and clinical-site capacity cannot substitute for contracts, active use, or payer evidence.[CU001, CU007, CU010, CU011, CU012, CU015]

6.2 Clinical milestones are not commercial adoption

The clearest public adoption-adjacent signal is clinical progression: LifeMine's news page lists first-participant dosing in a first-in-human Phase 1 trial on April 8, 2025. The page also lists formation of an organ-transplant clinical advisory board on October 15, 2026. These are development and expert-engagement milestones, not disclosed customer deployments or trial-site counts. The assigned evidence includes no named participating center, patient outcomes, repeat purchasing, or utilization denominator. NMDP and provider directories can help diligence the transplant-site landscape, but a directory listing is not evidence that LifeMine selected or contracted with any listed institution.[CU002, CU003, CU006, CU013]

6.3 Named counterparties do not yet establish a customer base

GSK is the clearest named commercial-side counterparty in the assigned sources: Fierce Biotech describes a 2022 R&D alliance to develop three drug candidates, while a 2026 third-party profile reports GSK among Series E participants. Neither fact establishes that the alliance remains operational, that a product has been sold, or what economics accrue to LifeMine. Fierce also reported restructuring as the company prioritized its lead clinical program and said the number of affected staff had not been disclosed at press time. The selected transplant centers in the table are ecosystem examples only; the sources do not identify them as LifeMine customers, trial sites, or reference accounts.[CU004, CU005, CU013, CU015]

6.4 Durability and expansion remain unmeasured

The assigned evidence provides no customer count, revenue generated from product sales, renewal or retention rate, cohort data, contract duration, concentration measure, or center-level outcome. The B2B/product-sales classification is therefore a business-model description, not a traction metric. For a clinical-stage asset, the path from discovery to durable commercial use still depends on clinical validation, regulatory decisions, site operations, and payer or partner economics; the reviewed sources do not document those downstream gates as completed. Diligence should request the current GSK agreement scope and economics, trial-site roster and enrollment denominators, and any paid collaborations or product revenue, then verify renewals and customer concentration against contracts and finance records.[CU001, CU005, CU013, CU014, CU016]

7.1 Clinical, regulatory, and intellectual-property exposure

LifeMine identifies LIFE-001 as its lead clinical-stage program and its news page lists an April 2025 first-participant dose in a first-in-human Phase 1 trial (CR001, CR002). The company describes a clinical advisory board that will advise on development, but that is an oversight mechanism, not efficacy, safety, or regulatory validation (CR003). The assigned company pages do not provide trial outcomes or a regulator-record identifier (CR014); they therefore cannot establish safety, efficacy, approval status, or the probability of success. WIPO's general biotechnology guidance emphasizes the financing and commercialization importance of patent rights and freedom-to-operate analysis, but does not assess LifeMine's portfolio (CR010, CR011). Obtain the trial package and a company-specific IP/FTO review before treating either risk as mitigated.[CR001, CR002, CR003, CR010, CR011, CR014]

7.2 Operating concentration and execution transition

Fierce Biotech reported that LifeMine was reducing staff and redirecting resources toward clinical development; the CEO described a “rebalancing of capital and personnel,” while the article said the company did not disclose the number affected or whether LIFE-001 had become its only asset (CR007). The same report relayed the CEO's statement that internal operations were being consolidated into a 55,000-square-foot Watertown facility and that a large external R&D force was part of the transition (CR008). These are reported changes, not proof of a quality failure or clinical delay. The current source set does not identify the external providers, staffing baseline, quality controls, or continuity plan. Diligence should test whether trial execution, vendor oversight, and facilities remain adequately resourced.[CR007, CR008, CR013, CR014]

7.3 Partner and capital dependencies

Goodwin reports $263 million of financing across a $75 million Series D closed in 2025 and a $188 million Series E completed in July 2026; LifeMine's own site says total funding raised is $558 million (CR004, CR005, CR006). These are financing disclosures, not cash available, revenue, or runway. Fierce reported that the current status of LifeMine's GSK collaboration was unclear at publication and that the parties had not answered its questions (CR009). The sources also do not identify the terms, rights, milestones, economics, or termination provisions of that relationship. Request current cash and burn data alongside the executed partner agreements; until then, capital adequacy and partner optionality cannot be assessed from round size alone.[CR004, CR005, CR006, CR009, CR015]

7.4 Monitoring gates and thesis-break conditions

Monitoring should focus on evidence that can change the clinical and financing assessment: the next disclosed LIFE-001 safety and pharmacology data, trial progress against company-provided milestones, any confirmed change in the active pipeline, and a documented current status for the GSK relationship (CR002, CR007, CR009, CR014). A material safety signal, a regulatory hold, inability to fund the next clinical milestone, or loss of a critical partner would warrant a thesis reset; these are diligence triggers, not events established by the assigned sources. LifeMine's careers page warns applicants about recruiting impersonation and sensitive-information requests, but it reports no confirmed security incident (CR012). The missing cash, trial, partner, and IP records are material diligence gaps, not evidence that an adverse event has occurred.[CR002, CR007, CR009, CR012, CR014, CR015, CR016]

7.5 Exhibits

8.1 Entry decision and valuation evidence

LifeMine's official news page lists an August 6, 2026 announcement titled “LifeMine Raises $263 Million”; Fierce Biotech reports that the financing combined a $188 million Series E with a previously completed $75 million Series D. Startuprise repeats a $558 million cumulative amount raised. These are financing amounts, not a disclosed post-money valuation, current cash balance, or investor return. The retrieved financing coverage gives no price per share, capitalization table, or liquidation-preference waterfall. Accordingly, the evidence supports a track / research-more decision, not a numeric fair-value opinion: do not underwrite a fresh entry at an undisclosed price. Confidence is medium on this evidence-based decision and low on fair value; the clinical and financing risk is high.[CV001, CV002, CV003, CV004, CV013, CV015]

8.2 Investment thesis and anti-thesis

The upside case is a platform with a company-reported library of 100,000 deep-sequenced fungal strains across more than 25,000 species, paired with a lead asset that the company says is in a first-in-human Phase 1 study. LifeMine's pipeline page says kidney- and islet-cell-transplant studies are expected to begin in early 2027. These are meaningful development milestones, but platform scale is not proof of reproducible discovery economics, and a company description is not independent confirmation of clinical benefit. The counterweight is execution and concentration risk: Fierce reported that the platform had been put on ice during a prior period of austerity and that the GSK discovery alliance had stalled after GSK reprioritized internally. The new financing changes the funding context; it does not erase the need to establish clinical differentiation, partnership economics, and a capital-efficient path to the next value inflection. LifeMine reports a Watertown headquarters and additional offices in Gloucester and Basel, but those locations disclose no staffing or cost denominator.[CV005, CV006, CV007, CV008, CV009, CV010, CV014, CV016]

8.3 Scenarios and entry discipline

Bull, base, and bear cases can be framed as milestone paths, but a defensible equity or enterprise-value range cannot be calculated from these sources: the latest financing price, fully diluted share count, preference stack, cash and burn, and clinical outcome probabilities are not supplied. Fierce attributes a $25–$30 billion opportunity to the CEO if LIFE-001 is approved; the article does not specify a revenue period, denominator, or independently validated market model, so this is not treated as revenue, addressable market, or a valuation input. Companies Market Cap reports Eledon Pharmaceuticals' market capitalization at $0.18 billion on October 25, 2026. That is one public-company market snapshot, not a directly comparable valuation benchmark for LifeMine. Entry discipline is therefore binary rather than price-target based: revisit only after disclosed financing terms and clinical evidence can support a probability-weighted model; do not fill missing inputs with unsupported multiples or scenario probabilities.[CV002, CV003, CV005, CV011, CV012, CV013, CV015]

8.4 Exit readiness and diligence gates

The path from financing to investable value runs through clinical proof, disclosed ownership economics, and an executable development plan. The company identifies LIFE-001 as a Phase 1 program and expects transplant studies in early 2027; these are forward-looking milestones, not achieved outcomes. No exit value, liquidity route, or return horizon is supportable from the retained evidence. Before underwriting, obtain the Series E price and fully diluted capitalization, preferred rights and seniority, current cash and burn with milestone runway, protocol and independent safety/PK/PD data, trial timelines, and the GSK alliance's rights and economics. Reassess if studies are delayed, safety or efficacy fails to differentiate LIFE-001, the platform remains single-asset dependent, or the funding terms imply dilution or preferences that absorb plausible exit proceeds.[CV006, CV008, CV010, CV013, CV015]

8.5 Exhibits